Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Advanced Micro Devices
AMD
|
+$1.32B |
| 2 |
AstraZeneca
AZN
|
+$733M |
| 3 |
Microsoft
MSFT
|
+$728M |
| 4 |
Cadence Design Systems
CDNS
|
+$720M |
| 5 |
Moody's
MCO
|
+$359M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alcon
ALC
|
+$1.43B |
| 2 |
Estee Lauder
EL
|
+$872M |
| 3 |
Eli Lilly
LLY
|
+$626M |
| 4 |
Netflix
NFLX
|
+$521M |
| 5 |
UnitedHealth
UNH
|
+$466M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 33.19% |
| 2 | Consumer Discretionary | 19.62% |
| 3 | Healthcare | 16.16% |
| 4 | Financials | 9.12% |
| 5 | Communication Services | 8.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
Jazz Pharmaceuticals
JAZZ
$15.8B
| $66M | 0.06% |
451,265
-10,848
| -2% | -$1.6M |
|
152
BioMarin Pharmaceuticals
BMRN
$11.5B
| $65.6M | 0.06% |
674,108
+95,485
| +17% | +$9.9M |
|
153
Enphase Energy
ENPH
$5.3B
| $65.5M | 0.06% |
311,338
-988,681
| -76% | -$214M |
|
154
e.l.f. Beauty
ELF
$4.99B
| $64.9M | 0.06% |
787,951
-279,878
| -26% | -$18.9M |
|
155
CONMED
CNMD
$1.52B
| $64.9M | 0.06% |
624,710
+5,374
| +0.9% | +$520K |
|
156
Dominion Energy
D
$59.8B
| $64.1M | 0.06% |
1,145,872
+553,380
| +93% | +$32.4M |
|
157
Kontoor Brands
KTB
$4.78B
| $63.8M | 0.06% |
1,318,691
-472,331
| -26% | -$22.4M |
|
158
Century Communities
CCS
$2B
| $63.8M | 0.06% |
997,554
+12,828
| +1% | +$765K |
|
159
Lowe's Companies
LOW
$120B
| $63.4M | 0.06% |
317,274
+26,616
| +9% | +$5.41M |
|
|
PYCR
160
DELISTED
Paycor HCM, Inc. Common Stock
PYCR
| $59.1M | 0.05% |
2,228,275
+274,921
| +14% | +$6.8M |
|
161
Churchill Downs
CHDN
$5.98B
| $58.9M | 0.05% |
458,476
+21,606
| +5% | +$2.61M |
|
162
Etsy
ETSY
$8.11B
| $58.4M | 0.05% |
524,297
+246,821
| +89% | +$30.6M |
|
163
Pinnacle Financial Partners Inc
PNFP
$16.4B
| $58.3M | 0.05% |
1,056,277
+110,458
| +12% | +$7.75M |
|
164
Saia
SAIA
$9.7B
| $57.5M | 0.05% |
211,487
-15,701
| -7% | -$4.19M |
|
165
Cactus
WHD
$5.12B
| $57.4M | 0.05% |
1,392,391
+291,789
| +27% | +$14.1M |
|
166
Blackstone
BX
$109B
| $57M | 0.05% |
649,092
-91,279
| -12% | -$8.06M |
|
167
Ero Copper
ERO
$2.96B
| $57M | 0.05% |
3,224,545
+26,008
| +0.8% | +$419K |
|
168
Celldex Therapeutics
CLDX
$2.96B
| $56.9M | 0.05% |
1,582,090
+26,772
| +2% | +$1.16M |
|
169
HEICO Corp
HEI
$51B
| $56.8M | 0.05% |
331,910
+757
| +0.2% | +$127K |
|
170
Icon
ICLR
$12B
| $56.3M | 0.05% |
263,751
-4,151
| -2% | -$924K |
|
171
Agilent Technologies
A
$38.8B
| $55.9M | 0.05% |
404,228
-18,462
| -4% | -$2.7M |
|
|
CDMO
172
DELISTED
Avid Bioservices, Inc. Common Stock
CDMO
| $55.2M | 0.05% |
2,942,576
+13,412
| +0.5% | +$220K |
|
|
NSA
173
DELISTED
National Storage Affiliates Trust
NSA
| $54.4M | 0.05% |
1,301,185
-59,843
| -4% | -$2.42M |
|
174
Boston Scientific
BSX
$70.3B
| $54.1M | 0.05% |
+1,082,046
| New | +$51M |
|
175
Vaxcyte
PCVX
$7.77B
| $53.6M | 0.05% |
1,430,039
+8,032
| +0.6% | +$341K |
|
Similar funds
Jennison Associates's Q1 2023 Portfolio in Review
As of Q1 2023, Jennison Associates held 644 positions worth $109B, up 10% from $98.7B the previous quarter. Its ten largest holdings account for 39% of the portfolio.
Jennison Associates withdrew a net $3.94B in Q1 2023, closing 63 positions and reducing 280 holdings. Its most notable exit was Alcon, an estimated $1.43B position sold in full.
By sector, the portfolio is most concentrated in Technology at 33% of assets, up from 26% a quarter earlier, followed by Consumer Discretionary and Healthcare.
Against the trend, Jennison Associates opened a new position in Advanced Micro Devices worth $1.59B.
- Jennison Associates's largest Q1 2023 buy was Advanced Micro Devices: 16,272,765 shares worth $1.59B.
- Jennison Associates added most to AstraZeneca in Q1 2023, an estimated $733M increase.
- Jennison Associates's biggest Q1 2023 reduction was Estee Lauder, cutting an estimated $872M.
- Jennison Associates fully exited Alcon in Q1 2023, selling an estimated $1.43B.
- Jennison Associates's ten largest holdings make up 39% of its $109B portfolio in Q1 2023.
- Jennison Associates opened 73 new positions and closed 63 in Q1 2023.
- Jennison Associates's portfolio value rose 10% quarter-over-quarter to $109B.
Based on Jennison Associates's 13F filing for Q1 2023, filed 26 Apr 2023.